Roivant Sciences (ROIV) Set to Announce Earnings on Tuesday

Roivant Sciences (NASDAQ:ROIV) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Roivant Sciences to post earnings of ($0.21) per share for the quarter. Investors interested in participating in the company’s conference call can do so using this link.

Roivant Sciences (NASDAQ:ROIV) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating the consensus estimate of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The company had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same period last year, the firm posted ($0.38) earnings per share. Roivant Sciences’s revenue was up 155.1% compared to the same quarter last year. On average, analysts expect Roivant Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Roivant Sciences Price Performance

ROIV opened at $11.87 on Friday. The company’s 50-day simple moving average is $11.79 and its two-hundred day simple moving average is $11.29. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. The stock has a market capitalization of $8.78 billion, a P/E ratio of 2.13 and a beta of 1.24. Roivant Sciences has a 52-week low of $8.47 and a 52-week high of $13.06.

Insider Buying and Selling

In other news, COO Eric Venker sold 100,000 shares of the company’s stock in a transaction on Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the sale, the chief operating officer now owns 617,470 shares of the company’s stock, valued at $7,193,525.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction dated Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the sale, the chief operating officer now directly owns 617,470 shares of the company’s stock, valued at approximately $7,193,525.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Financial Lp Qvt sold 876,000 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The shares were sold at an average price of $11.82, for a total value of $10,354,320.00. Following the completion of the sale, the director now directly owns 22,179,358 shares in the company, valued at approximately $262,160,011.56. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 3,577,309 shares of company stock valued at $42,151,184. 7.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on ROIV. Bank of America increased their price target on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Cantor Fitzgerald reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research report on Thursday, September 19th. One analyst has rated the stock with a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.39.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.